Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Kojin Therapeutics is raising $60,216,451.00 in new funding. Sources indicate as part of senior management President, Susan Langer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kojin Therapeutics
We translate our deep biological insight into cell states to small-molecule therapeutics. Our approach opens new avenues for the treatment of cancer, fibrosis, ischemia, and immune modulation. Kojin is harnessing groundbreaking discoveries in cell state and ferroptosis biology to create novel therapies and cures for diseases traditionally considered intractable. By connecting complex cell states to known biochemical processes, Kojin has developed a proprietary approach to ferroptosis-based drug discovery that enables development of selective therapies for a broad range of debilitating diseases. Kojin is founded by leading scientists Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan.

To learn more about Kojin Therapeutics, visit http://kojintx.com/

Contact:
Susan Langer, President
781-299-7800
slanger@kojintx.com
https://www.linkedin.com/in/susan-langer-24b1513b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved